Cargando…

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP

BACKGROUND: Anthracycline-induced cardiotoxicity is an irreversible cardiac cell injury. Therefore, it’s very important to identify influencing factors of anthracycline-induced subclinical cardiotoxicity (AISC). This study was designed to analyze the influencing factors of AISC in patients with diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Qian, Ou, Wenxin, Wang, Mei, Jiang, Tiantian, Weng, Yue, Zhou, Xi, Tang, Xiaoqiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482309/ https://www.ncbi.nlm.nih.gov/pubmed/36115970 http://dx.doi.org/10.1186/s12885-022-10085-6

Ejemplares similares

Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients
por: Zhou, Xi, et al.
Publicado: (2023)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
por: Hu, Hui-Min, et al.
Publicado: (2018)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
por: Lorenz, K., et al.
Publicado: (2022)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014)

Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)

Metabolic Aspects of Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021)

Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022)

Anthracycline-induced cardiotoxicity and senescence
por: Booth, Laura K., et al.
Publicado: (2022)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
por: Wang, Di, et al.
Publicado: (2020)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
por: Volkova, Maria, et al.
Publicado: (2011)

Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016)

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

Coronary microcirculation damage in anthracycline cardiotoxicity
por: Galán-Arriola, Carlos, et al.
Publicado: (2021)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
por: Vuong, Jacqueline T., et al.
Publicado: (2022)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
por: Chung, Woo-Baek, et al.
Publicado: (2016)

What is considered cardiotoxicity of anthracyclines in animal studies
por: Georgiadis, Nikolaos, et al.
Publicado: (2020)

What is considered cardiotoxicity of anthracyclines in animal studies
por: Georgiadis, Nikolaos, et al.
Publicado: (2020)

Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle
por: Liu, Jennifer E.
Publicado: (2020)

The Interplay Between Autophagy and Senescence in Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021)

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect
por: Huang, Junqi, et al.
Publicado: (2022)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
por: Ibanez, Borja, et al.
Publicado: (2022)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
por: Tantawy, Marwa, et al.
Publicado: (2020)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
por: Sobiborowicz-Sadowska, Aleksandra M., et al.
Publicado: (2023)

Metformin to Prevent Anthracycline Cardiotoxicity?: That Would Be Sweet!
por: El-Rayes, Malak, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ecsm55ijb7o5f9sm84qdbcum7o